Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.06.4618 on April 9 2007

Journal of Clinical Oncology, Vol 25, No 15 (May 20), 2007: pp. 1986-1992
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herold, M.
Right arrow Articles by von Grünhagen, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herold, M.
Right arrow Articles by von Grünhagen, U.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

Michael Herold, Antje Haas, Stefanie Srock, Sabine Neser, Kathrin Haifa Al-Ali, Andreas Neubauer, Gottfried Dölken, Ralph Naumann, Wolfgang Knauf, Mathias Freund, Robert Rohrberg, Klaus Höffken, Astrid Franke, Thomas Ittel, Erika Kettner, Ursula Haak, Ulrich Mey, Christian Klinkenstein, Michael Aßmann, Ullrich von Grünhagen

From the HELIOS Klinikum Erfurt GmbH, Erfurt; Klinikum Ernst von Bergmann, Potsdam; Charité, Rudolph-Virchow-Klinikum; Charité, Campus Klinikum Benjamin Franklin, Berlin; Klinikum Chemnitz, Chemnitz; Klinikum der Universität Leipzig, Leipzig; Klinikum der Philips Universität Marburg, Marburg; Klinikum der Ernst-Moritz-Arndt Universität, Greifswald; Klinikum der Technischen Universität Dresden, Dresden; Onkologische Schwerpunktpraxis Frankfurt/Main, Frankfurt/Main; Klinikum der Universität Rostock, Rostock; Onkologische Schwerpunktpraxis; Städitisches Krankenhaus Martha-Maria Halle-Dölau, Halle; Klinikum der Friedrich-Schiller-Universität, Jena; Klinikum der Otto-von-Guericke-Universität; Städtisches Klinikum Magdeburg, Magdeburg; Klinikum der Hansestadt Stralsund GmbH, Stralsund; Klinikum der Rheinischen Friedrich-Wilhelms Universität Bonn, Bonn; Klinikum Frankfurt/Oder, Frankfurt; Krankenhaus Riesa, Riesa; and Onkologische Schwerpunktpraxis, Cottbus, Germany

Address reprint requests to Michael Herold, MD, HELIOS Klinikum Erfurt GmbH, 2 Medizinische Klinik, Bereich Hamatologie/Onkologie, Nordhauserstr 74, 99089, Erfurt, Germany; e-mail: miherold{at}erfurt.helios-kliniken.de

Purpose Rituximab has been shown to be active in follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. We conducted a randomized trial comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus rituximab with MCP alone.

Patients and Methods Previously untreated patients with stage III or IV CD20+ indolent or mantle cell lymphoma were randomly assigned to either eight 28-day cycles of MCP plus rituximab (R-MCP; n = 181) or eight cycles of MCP alone (n = 177). All patients who achieved a complete or partial remission were treated with interferon maintenance until relapse. Herein, we report the results from the primary analysis population of patients with FL, who constituted the majority of patients (56%) recruited to the trial (n = 201; R-MCP, n = 105; MCP, n = 96).

Results Rates of overall and complete response were significantly higher in the R-MCP arm than the MCP arm (overall response, 92% v 75%, respectively; P = .0009; complete response, 50% v 25%, respectively; P = .004). With a median follow-up time of 47 months, median event-free survival (EFS) and progression-free survival (PFS) times were significantly prolonged with R-MCP compared with MCP (EFS, not reached v 26 months, respectively; P < .0001; PFS, not reached v 28.8 months, respectively; P < .0001), and overall survival (OS) was significantly improved with R-MCP compared with MCP (4-year OS rate, 87% v 74%, respectively; P = .0096).

Conclusion The R-MCP regimen significantly improves complete and overall response rates, EFS, PFS, and OS in patients with previously untreated advanced FL, without a clinically significant increase in toxicity.

published online ahead of print at www.jco.org on April 9, 2007.

Supported by grants from F. Hoffmann–La Roche Ltd, Germany.

Presented in part at the 46th Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego, CA; the 9th International Conference on Malignant Lymphoma, June 8-11, 2005, Lugano, Switzerland; and the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
J.-L. Harousseau, M. Attal, and H. Avet-Loiseau
The role of complete response in multiple myeloma
Blood, October 8, 2009; 114(15): 3139 - 3146.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence
Oncologist, October 1, 2009; 14(suppl_2): 17 - 29.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. H.M. Keegan, L. A. McClure, J. M. Foran, and C. A. Clarke
Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study
J. Clin. Oncol., June 20, 2009; 27(18): 3044 - 3051.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Z. Ai, R. Tibshirani, B. Taidi, D. Czerwinski, and R. Levy
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
Blood, June 4, 2009; 113(23): 5743 - 5746.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Hiraga, A. Tomita, T. Sugimoto, K. Shimada, M. Ito, S. Nakamura, H. Kiyoi, T. Kinoshita, and T. Naoe
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Blood, May 14, 2009; 113(20): 4885 - 4893.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. S. Hayden-Ledbetter, C. G. Cerveny, E. Espling, W. A. Brady, L. S. Grosmaire, P. Tan, R. Bader, S. Slater, C. A. Nilsson, D. S. Barone, et al.
CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells
Clin. Cancer Res., April 15, 2009; 15(8): 2739 - 2746.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. Hochster, E. Weller, R. D. Gascoyne, T. M. Habermann, L. I. Gordon, T. Ryan, L. Zhang, N. Colocci, S. Frankel, and S. J. Horning
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
J. Clin. Oncol., April 1, 2009; 27(10): 1607 - 1614.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Hagenbeek
Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand?
J. Clin. Oncol., April 1, 2009; 27(10): 1540 - 1542.
[Full Text] [PDF]


Home page
JCOHome page
B. D. Cheson and M. J. Rummel
Bendamustine: Rebirth of an Old Drug
J. Clin. Oncol., March 20, 2009; 27(9): 1492 - 1501.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Gyan, C. Foussard, P. Bertrand, P. Michenet, S. Le Gouill, C. Berthou, H. Maisonneuve, V. Delwail, R. Gressin, P. Quittet, et al.
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years
Blood, January 29, 2009; 113(5): 995 - 1001.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Salles, N. Mounier, S. de Guibert, F. Morschhauser, C. Doyen, J.-F. Rossi, C. Haioun, P. Brice, B. Mahe, R. Bouabdallah, et al.
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Blood, December 15, 2008; 112(13): 4824 - 4831.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Morschhauser, J. Radford, A. Van Hoof, U. Vitolo, P. Soubeyran, H. Tilly, P. C. Huijgens, A. Kolstad, F. d'Amore, M. G. Diaz, et al.
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
J. Clin. Oncol., November 10, 2008; 26(32): 5156 - 5164.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
O. W. Press
Evidence Mounts for the Efficacy of Radioimmunotherapy for B-Cell Lymphomas
J. Clin. Oncol., November 10, 2008; 26(32): 5147 - 5150.
[Full Text] [PDF]


Home page
JCOHome page
R. Marcus, K. Imrie, P. Solal-Celigny, J. V. Catalano, A. Dmoszynska, J. C. Raposo, F. C. Offner, J. Gomez-Codina, A. Belch, D. Cunningham, et al.
Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
J. Clin. Oncol., October 1, 2008; 26(28): 4579 - 4586.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. J. Horning
Follicular Lymphoma, Survival, and Rituximab: Is It Time to Declare Victory?
J. Clin. Oncol., October 1, 2008; 26(28): 4537 - 4538.
[Full Text] [PDF]


Home page
CA Cancer J ClinHome page
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
C. Herbst, I. Monsef, N. Skoetz, and A. Engert
Eighth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Chronic Lymphatic Leukemia
J Natl Cancer Inst, August 6, 2008; 100(15): E1 - E1.
[Full Text] [PDF]


Home page
JCOHome page
C. Sebban, P. Brice, R. Delarue, C. Haioun, B. Souleau, N. Mounier, N. Brousse, P. Feugier, H. Tilly, P. Solal-Celigny, et al.
Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study
J. Clin. Oncol., July 20, 2008; 26(21): 3614 - 3620.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Hagenbeek, O. Gadeberg, P. Johnson, L. Moller Pedersen, J. Walewski, A. Hellmann, B. K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, et al.
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Blood, June 15, 2008; 111(12): 5486 - 5495.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist, June 1, 2008; 13(6): 657 - 667.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood, May 1, 2008; 111(9): 4664 - 4667.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica, November 1, 2007; 92(11): 1533 - 1548.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology, January 1, 2007; 2007(1): 216 - 225.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online